Loading data for DRUG — first visit, this takes a few seconds.

Alerta

Bright Minds Biosciences ... (DRUG)

NasdaqCM: DRUG · Precio en tiempo real · USD

84.74

+0.70 (0.83%)

Al cierre: Aug 19, 2026, 8:00 PM

84.74

+0.00%

Fuera de horario: 7:30 PM

0.83% (1D)

No hay datos disponibles

Precio de compra	78.65
Capitalización de mercado	831.47M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-24.51M
Beta	0.09
EPS (TTM)	-2.05
Ratio PER (TTM)	n/a
Adelante PE	-13.19
P/B (TTM)	3.75
P/S (TTM)	n/a
Earnings Date	Dec 22, 2026

Precio de venta	80.03
Volumen	115,927
Volumen medio (20D)	309,995
Abierto	85.80
Anterior Cerrar	84.04
Rango del día	83.24 - 87.00
Rango de 52 semanas	38.00 - 123.75
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de DRUG

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathi...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Mar 22, 2021

Empleados 26

Bolsa de Valores NasdaqCM

Símbolo bursátil DRUG

Sitio web https://brightmindsbio.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Bright Minds Biosciences fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -12.23M, un aumento de 336.46%.

Estados financieros

Sorpresa de resultados

Bright Minds Biosciences ha publicado sus resultados trimestrales en Aug 14, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.24 supera las estimaciones en 1.40, con 67.57% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Bright Minds Biosciences Inc. publique sus resultados el Dec 22, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet

The mean of analysts' price targets for Bright Minds Biosciences Inc. (DRUG) points to a 97.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ag...

3 semanas hace · Zacks

Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?

The consensus price target hints at a 107.5% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward tren...

4 semanas hace · Zacks

All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy

Bright Minds Biosciences Inc. (DRUG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

3 meses hace · Motley Fool

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model.

4 meses hace · Insider Monkey

What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

Bright Minds Biosciences Inc (NASDAQ:DRUG) is among the best psychedelic stocks to buy in 2026. The company has multiple psychedelic drug candidates, including potential medicines for epilepsy. Its fl...

Página 1 de 2